| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Cytidine metabolism pathways, DNA synthesis. As a cytidine analog, 3'-Deoxycytidine is incorporated into DNA but lacks the 3'-hydroxyl group needed for chain elongation, acting as a chain terminator. The compound targets rapidly dividing cells and viral replication.
|
|---|---|
| ln Vitro |
3'-Deoxycytidine demonstrates activity as a cytidine nucleoside analog and DNA chain terminator in cellular assays. Nucleoside analogs have applications in cancer and antiviral research. Detailed IC50 values have not been disclosed. The compound is primarily used as a research tool.
|
| ln Vivo |
In vivo activity of 3'-Deoxycytidine has not been extensively characterized. As a chain-terminating nucleoside analog, it would be expected to have activity in animal models of cancer or viral infection. In vivo studies would be needed to evaluate its therapeutic potential.
|
| Enzyme Assay |
In vitro assays for cytidine nucleoside analogs involve measuring inhibition of DNA synthesis. The compound is incubated with cancer cells, and DNA synthesis inhibition is measured by radiolabeled thymidine incorporation. Cell viability is assessed by MTT assays.
|
| Cell Assay |
Cells are cultured and treated with 3'-Deoxycytidine at concentrations typically ranging from 0.1–100 μM for 24–72 hours. DNA synthesis inhibition is measured by BrdU incorporation. Cell viability is assessed by standard assays.
|
| Animal Protocol |
In vivo animal studies have not been reported. The compound is primarily used as a research tool. Future studies in xenograft or viral infection models would be needed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data have not been published. The compound is a cytidine analog with expected cellular uptake. In vivo PK parameters have not been characterized.
|
| Toxicity/Toxicokinetics |
Toxicology data have not been published. The compound is for research use only and not approved for human therapeutic applications.
|
| References | |
| Additional Infomation |
3'-Deoxycytidine (CAS: 7057-33-2) is a cytidine nucleoside analog and DNA chain terminator. It is used in nucleoside analog research. It is not in clinical trials and has no regulatory approval.
|
| Molecular Formula |
C9H13N3O4
|
|---|---|
| Molecular Weight |
227.22
|
| Exact Mass |
227.09
|
| CAS # |
7057-33-2
|
| PubChem CID |
145986
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
497.6±55.0 °C at 760 mmHg
|
| Flash Point |
254.8±31.5 °C
|
| Vapour Pressure |
0.0±2.9 mmHg at 25°C
|
| Index of Refraction |
1.720
|
| LogP |
-1.7
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
16
|
| Complexity |
355
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C1[C@H](O[C@H]([C@@H]1O)N2C=CC(=NC2=O)N)CO
|
| InChi Key |
ZHHOTKZTEUZTHX-SHYZEUOFSA-N
|
| InChi Code |
InChI=1S/C9H13N3O4/c10-7-1-2-12(9(15)11-7)8-6(14)3-5(4-13)16-8/h1-2,5-6,8,13-14H,3-4H2,(H2,10,11,15)/t5-,6+,8+/m0/s1
|
| Chemical Name |
4-amino-1-[(2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~440.1 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.00 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4010 mL | 22.0051 mL | 44.0102 mL | |
| 5 mM | 0.8802 mL | 4.4010 mL | 8.8020 mL | |
| 10 mM | 0.4401 mL | 2.2005 mL | 4.4010 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
